Recently, it was found that in Thy1-C/EBPβ transgenic AD model mice, treatment with PGE2 elicited AD-like pathologies [129], possibly due to the binding of more proinflammatory receptors, such as EP2. The gene discussed is CEBPB; the disease is Alzheimer disease.